02
03
Alongside a portfolio of in-house therapeutic antibodies for neuro-oncology indications, Nanocarry is seeking partnerships with pharma and biotech companies to leverage the AxS platform to co-develop the next generation of therapeutics for patients living with CNS diseases.
A co-development strategy with partners will pave the way for a new era of drug innovation, creating infinite possibilities to go beyond the “shuttle” nature of the AxS platform and leverage it to create multidrug modalities and new mechanisms of action to treat CNS indications for which no biologics are currently approved.
designed by Studio7Design